Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease

The clinical features have been well described in obese chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD). However, little is known about the clinical features of lean CHB‐NAFLD patients.

[1]  P. Fariselli,et al.  Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? , 2021, Gut.

[2]  A. Dhawan,et al.  NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.

[3]  J. Kao,et al.  East Asia expert opinion on treatment initiation for chronic hepatitis B , 2020, Alimentary pharmacology & therapeutics.

[4]  K. Reddy,et al.  Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  C. Stave,et al.  Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[6]  H. Janssen,et al.  Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B , 2020, Hepatology.

[7]  Q. Xie,et al.  Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  Marialena Mouzaki,et al.  Lean non-alcoholic fatty liver disease. , 2019, Clinical nutrition.

[9]  V. Wong,et al.  Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. , 2019, The lancet. Gastroenterology & hepatology.

[10]  Yeojun Yun,et al.  Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects , 2019, PloS one.

[11]  E. Bugianesi,et al.  NASH in Lean Individuals , 2019, Seminars in Liver Disease.

[12]  M. Huang,et al.  Lean non‐alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non‐alcoholic fatty liver disease patients , 2018, Journal of gastroenterology and hepatology.

[13]  Sebastian K. Eder,et al.  Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients , 2018, Journal of clinical medicine.

[14]  Q. Ning,et al.  Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model , 2018, Hepatology International.

[15]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis , 2018, Diabetes Care.

[16]  S. Sookoian,et al.  Systematic review with meta‐analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease , 2018, Alimentary pharmacology & therapeutics.

[17]  M. Yuen,et al.  Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case‐control study , 2018, Journal of viral hepatitis.

[18]  R. Hultcrantz,et al.  Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study , 2017, Hepatology communications.

[19]  A. Gasbarrini,et al.  Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[20]  M. Yuen,et al.  Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[22]  D. Consonni,et al.  Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  J. Kao,et al.  Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study , 2017, Hepatology.

[24]  A. Tuttolomondo,et al.  Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease , 2017, Hepatology.

[25]  A. Unalp‐Arida,et al.  Liver fibrosis scores predict liver disease mortality in the United States population , 2017, Hepatology.

[26]  N. Pausawasdi,et al.  The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[27]  E. Gorospe,et al.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. , 2017, Gastroenterology.

[28]  Y. Taşova,et al.  Clinical features of chronic hepatitis B patients , 2017 .

[29]  V. Wong,et al.  Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B , 2017, Journal of gastroenterology and hepatology.

[30]  V. Wong,et al.  Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients , 2017, Hepatology.

[31]  Sebastian K. Eder,et al.  Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver , 2017, The American Journal of Gastroenterology.

[32]  P. Gluckman,et al.  Obesity and the health of future generations. , 2016, The lancet. Diabetes & endocrinology.

[33]  M. M. Rahman,et al.  Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .

[34]  M. Fincancı,et al.  Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. , 2016, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[35]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[36]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[37]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[38]  V. Wong,et al.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015, Nature Communications.

[39]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[40]  Y. Yılmaz,et al.  Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels , 2015, Scandinavian journal of gastroenterology.

[41]  V. Wong,et al.  PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome , 2014, Alimentary pharmacology & therapeutics.

[42]  K. Yamaguchi,et al.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012 , 2014, Journal of Gastroenterology.

[43]  H. Garg,et al.  Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? , 2013, Indian journal of endocrinology and metabolism.

[44]  Eliseo Guallar,et al.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. , 2013, American journal of epidemiology.

[45]  Q. Pan,et al.  Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model , 2012, Journal of gastroenterology and hepatology.

[46]  Young-Min Kwon,et al.  Association of Nonalcoholic Fatty Liver Disease With Components of Metabolic Syndrome According to Body Mass Index in Korean Adults , 2012, The American Journal of Gastroenterology.

[47]  M. Yuen,et al.  The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction? , 2012, Digestive Diseases and Sciences.

[48]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[49]  V. Wong,et al.  Hepatitis B virus infection and fatty liver in the general population. , 2012, Journal of hepatology.

[50]  H. Cortez‐Pinto,et al.  Liver and Muscle in Morbid Obesity: The Interplay of Fatty Liver and Insulin Resistance , 2012, PloS one.

[51]  C. Chu,et al.  Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without , 2012, Digestive Diseases and Sciences.

[52]  T. Ninomiya,et al.  Impact of eating rate on obesity and cardiovascular risk factors according to glucose tolerance status: the Fukuoka Diabetes Registry and the Hisayama Study , 2012, Diabetologia.

[53]  H. Cortez‐Pinto,et al.  Hepatic steatosis in hepatitis B virus infected patients: Meta‐analysis of risk factors and comparison with hepatitis C infected patients , 2011, Journal of gastroenterology and hepatology.

[54]  B. Son,et al.  Hepatic steatosis and fibrosis in young men with treatment‐naïve chronic hepatitis B , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[55]  V. Wong,et al.  Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B , 2008, Gut.

[56]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[57]  Hao Wang,et al.  Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection , 2008, Journal of gastroenterology and hepatology.

[58]  Z. Younossi,et al.  Impact of non‐alcoholic fatty liver disease on chronic hepatitis B , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[59]  C. Chu,et al.  Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? , 2007, International Journal of Obesity.

[60]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[61]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[62]  D. Dimitropoulou,et al.  Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis , 2006, European journal of gastroenterology & hepatology.

[63]  C. Ahn,et al.  Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. , 2004, Archives of internal medicine.

[64]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[65]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[66]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[67]  P. Taylor,et al.  Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. , 2002, JAMA.

[68]  D. Pessayre,et al.  Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.

[69]  A. Joseph,et al.  Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. , 1991, Clinical radiology.

[70]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.